Multiple Myeloma

The FDA has approved daratumumab in combination with carfilzomib and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma who have received 1 or more prior lines of therapy.

Nina Shah MD, discusses the future of CAR T-cell therapy and bispecific antibodies in multiple myeloma.

Nina Shah, MD, discusses ​ongoing research with BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma.

In our exclusive interview, Marc J. Braunstein, MD, PhD, provides perspective on data in the upfront and relapsed/refractory settings regarding the use of triplet and quadruplet regimens, novel agents, and cellular therapies.

Nina Shah, MD, discusses the updated efficacy findings of JNJ-4528 from the phase 1b/2 CARTITUDE-1 study in relapsed/refractory multiple myeloma.

Nina Shah, MD, discusses the future of CAR T-cell therapy in multiple myeloma. 

Thomas G. Martin, MD, discusses the safety profile of belantamab mafodotin-blmf in relapsed/refractory multiple myeloma.

Betsy O'Donnell, MD, discusses ongoing research efforts in multiple myeloma.

A new subcutaneous formulation, daratumumab and hyaluronidase-fihj, provides similar efficacy in a more convenient and efficient regimen that is likely to change practice.

Noopur S. Raje, MD, discusses recent findings with melflufen in relapsed/refractory multiple myeloma.

Luciano J. Costa, MD, PhD, discusses unmet need​s in relapsed/refractory multiple myeloma. 

Sagar Lonial, MD, FACP, discusses the FDA approval of belantamab mafodotin in patients with relapsed/refractory multiple myeloma.

The FDA has approved belantamab mafodotin-blmf (Blenrep) as a treatment for patients with relapsed/refractory multiple myeloma who have received 4 prior therapies, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody.

Noopur S. Raje, MD, discusses remaining questions in multiple myeloma.